Publications
411 results found
Birrell MA, McCluskie K, Wong SS, et al., 2005, Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-κB-independent mechanism, FASEB JOURNAL, Vol: 19, Pages: 840-+, ISSN: 0892-6638
- Author Web Link
- Cite
- Citations: 140
McCluskie K, Birrell MA, Wong S, et al., 2004, Nitric oxide as a noninvasive biomarker of lipopolysaccharide-induced airway inflammation: Possible role in lung neutrophilia, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, Vol: 311, Pages: 625-633, ISSN: 0022-3565
- Author Web Link
- Cite
- Citations: 30
Usmani OS, Belvisi MG, Patel HJ, et al., 2004, Theobromine inhibits sensory nerve activation and cough, FASEB JOURNAL, Vol: 18, Pages: 231-+, ISSN: 0892-6638
- Author Web Link
- Cite
- Citations: 80
Morice AH, Fontana GA, Sovijarvi ARA, et al., 2004, The diagnosis and management of chronic cough, EUROPEAN RESPIRATORY JOURNAL, Vol: 24, Pages: 481-492, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 338
Belvisi MG, Hele DJ, Birrell MA, 2004, New anti-inflammatory therapies and targets for asthma and chronic obstructive pulmonary disease, EXPERT OPINION ON THERAPEUTIC TARGETS, Vol: 8, Pages: 265-285, ISSN: 1472-8222
- Author Web Link
- Cite
- Citations: 29
Belvisi MG, 2004, Sensory nerves as a target for therapeutic intervention in airway inflammatory diseases, FUNDAMENTAL & CLINICAL PHARMACOLOGY, Vol: 18, Pages: 20-20, ISSN: 0767-3981
Birrell MA, McCluskie K, Belvisi MG, 2004, Characterization of a pre-clinical model of airway inflammation: exhaled nitric oxide (exNO) as a non-invasive biomarker, FUNDAMENTAL & CLINICAL PHARMACOLOGY, Vol: 18, Pages: 105-105, ISSN: 0767-3981
Clarke DL, Belvisi MG, Smith S, et al., 2004, PGE2 augments G-CSF release from IL-1β-stimulated human airways smooth muscle cells by activating prostanoid receptors of the EP2-and EP4-subtype: role of PKA, FUNDAMENTAL & CLINICAL PHARMACOLOGY, Vol: 18, Pages: 59-59, ISSN: 0767-3981
Birrell MA, Patel HJ, McCluskie K, et al., 2004, PPAR-γ agonists as therapy for diseases involving airway neutrophilia, EUROPEAN RESPIRATORY JOURNAL, Vol: 24, Pages: 18-23, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 75
Belvisi MG, Geppetti P, 2004, Cough • 7:: Current and future drugs for the treatment of chronic cough, THORAX, Vol: 59, Pages: 438-440, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 27
Belvisi MG, Geppetti P, 2004, Cough. 7: Current and future drugs for the treatment of chronic cough., Thorax, Vol: 59, Pages: 438-440, ISSN: 0040-6376
There are currently no effective treatments for controlling the cough response with an acceptable therapeutic ratio. However, several new mechanisms have been identified which may lead to the development of new drugs.
Clarke DL, Belvisi MG, Catley MC, et al., 2004, Identification in human airways smooth muscle cells of the prostanoid receptor and signalling pathway through which PGE<sub>2</sub> inhibits the release of GM-CSF, BRITISH JOURNAL OF PHARMACOLOGY, Vol: 141, Pages: 1141-1150, ISSN: 0007-1188
- Author Web Link
- Cite
- Citations: 40
Clarke DL, Giembycz MA, Patel HJ, et al., 2004, E-ring 8-<i>iso</i>prostanes inhibit ACh release from parasympathetic nerves innervating guinea-pig trachea through agonism of prostanoid receptors of the EP<sub>3</sub>-subtype, BRITISH JOURNAL OF PHARMACOLOGY, Vol: 141, Pages: 600-609, ISSN: 0007-1188
- Author Web Link
- Cite
- Citations: 31
Belvisi MG, 2004, Ciclesonide - A viewpoint, DRUGS, Vol: 64, Pages: 520-520, ISSN: 0012-6667
Belvisi MG, Hele DJ, Birrell MA, 2004, New advances and potential therapies for the treatment of asthma, BIODRUGS, Vol: 18, Pages: 211-223, ISSN: 1173-8804
- Author Web Link
- Cite
- Citations: 19
Belvisi MG, 2004, Regulation of inflammatory cell function by corticosteroids., Proc Am Thorac Soc, Vol: 1, Pages: 207-214, ISSN: 1546-3222
Different inflammatory cell profiles are observed in the lungs of patients with asthma versus those with chronic obstructive pulmonary disease (COPD). In asthma, several key mediators have been implicated, including tumor necrosis factor-alpha and interleukin (IL)-1beta, together with cytokines derived from type 2 T-helper lymphocytes, such as IL-4, IL-5, and IL-13. In fact, inhibitors of IL-4 and IL-5 show promise as therapeutic agents. In COPD, the predominant inflammatory cell types are CD8(+) T lymphocytes, macrophages, and neutrophils. Glucocorticoids inhibit eosinophils in asthma, neutrophils in COPD and severe asthma, mast cells and basophils in asthma and COPD, and macrophages in COPD. However, it is generally assumed that neutrophils are less sensitive to glucocorticoids than are eosinophils and T cells, and that macrophages from patients with COPD are less sensitive to steroid treatment under certain circumstances. These differences in the responsiveness of activated inflammatory cells may help to explain why inhaled corticosteroid treatment has been more beneficial for patients with asthma than for patients with COPD.
Patel HJ, Birrell MA, Crispino N, et al., 2003, Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB2) receptor activation, BRITISH JOURNAL OF PHARMACOLOGY, Vol: 140, Pages: 261-268, ISSN: 0007-1188
- Author Web Link
- Cite
- Citations: 70
Robinson DS, Campbell DA, Durharm SR, et al., 2003, Systematic assessment of difficult-to-treat asthma, EUROPEAN RESPIRATORY JOURNAL, Vol: 22, Pages: 478-483, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 224
Belvisi MG, 2003, Airway sensory innervation as a target for novel therapies: an outdated concept?, CURRENT OPINION IN PHARMACOLOGY, Vol: 3, Pages: 239-243, ISSN: 1471-4892
- Author Web Link
- Cite
- Citations: 17
Birrell MA, Patel HJ, McCluskie K, et al., 2003, Peroxisome proliferator-activated receptor gamma (PPARγ) agonists:: A possible therapy for chronic obstructive pulmonary disease (COPD), Meeting of the British-Pharmacological-Society-Clinical-Pharmacology-Section, Publisher: NATURE PUBLISHING GROUP, Pages: U38-U38, ISSN: 0007-1188
Patel HJ, Birrell MA, Crispino N, et al., 2003, The effect of a cannabinoid (CB<sub>2</sub>) agonist on activation of airway sensory nerves in vitro and the cough reflex, Meeting of the British-Pharmacological-Society-Clinical-Pharmacology-Section, Publisher: NATURE PUBLISHING GROUP, Pages: U37-U37, ISSN: 0007-1188
Birrell MA, Battram CH, Woodman P, et al., 2003, Dissociation by steroids of eosinophilic inflammation from airway hyperresponsiveness in murine airways, Respiratory Research, Vol: 4, ISSN: 1465-9921
BackgroundThe link between eosinophils and the development of airway hyperresponsiveness (AHR) in asthma is still controversial. This question was assessed in a murine model of asthma in which we performed a dose ranging study to establish whether the dose of steroid needed to inhibit the eosinophil infiltration correlated with that needed to block AHR.MethodsThe sensitised BALB/c mice were dosed with vehicle or dexamethasone (0.01–3 mg/kg) 2 hours before and 6 hours after each challenge (once daily for 6 days) and 2 hours before AHR determination by whole-body plethysmography. At 30 minutes after the AHR to aerosolised methacholine the mice were lavaged and differential white cell counts were determined. Challenging with antigen caused a significant increase in eosinophils in the bronchoalveolar lavage (BAL) fluid and lung tissue, and increased AHR.ResultsDexamethasone reduced BAL and lung tissue eosinophilia (ED50 values of 0.06 and 0.08 mg/kg, respectively), whereas a higher dose was needed to block AHR (ED50 of 0.32 mg/kg at 3 mg/ml methacholine. Dissociation was observed between the dose of steroid needed to affect AHR in comparison with eosinophilia and suggests that AHR is not a direct consequence of eosinophilia.ConclusionThis novel pharmacological approach has revealed a clear dissociation between eosinophilia and AHR by using steroids that are the mainstay of asthma therapy. These data suggest that eosinophilia is not associated with AHR and questions the rationale that many pharmaceutical companies are adopting in developing low-molecular-mass compounds that target eosinophil activation/recruitment for the treatment of asthma.
Patel HJ, Belvisi MG, Bishop-Bailey D, et al., 2003, Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: Relevance for chronic obstructive pulmonary-disease therapy, JOURNAL OF IMMUNOLOGY, Vol: 170, Pages: 2663-2669, ISSN: 0022-1767
- Author Web Link
- Cite
- Citations: 110
Birrell MA, McCluskie K, Haddad EB, et al., 2003, Pharmacological assessment of the nitric-oxide synthase isoform involved in eosinophilic inflammation in a rat model of Sephadex-induced airway inflammation, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, Vol: 304, Pages: 1285-1291, ISSN: 0022-3565
- Author Web Link
- Cite
- Citations: 16
Belvisi MG, Bottomley KM, 2003, The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs?, INFLAMMATION RESEARCH, Vol: 52, Pages: 95-100, ISSN: 1023-3830
- Author Web Link
- Cite
- Citations: 139
Hele DJ, Belvisi MG, 2003, Novel therapies for the treatment of inflammatory airway disease., Expert Opin Investig Drugs, Vol: 12, Pages: 5-18, ISSN: 1354-3784
Asthma and chronic obstructive pulmonary disease (COPD) are diseases of the airways with an underlying inflammatory component. The prevalence and healthcare burden of asthma and COPD is still rising and is predicted to continue to rise in the current century. The beta-agonists and corticosteroids form the basis of the treatments available to alleviate the symptoms of asthma, whereas the treatments available for COPD have been shown to have a limited effect on slowing the progression of the disease. Asthma and COPD are both in need of novel, safe treatments to tackle the underlying inflammation that characterises their pathology. The inflammatory processes inherent in asthma and COPD provide the opportunity for innovative drug research. This review will outline the new approaches and targets being investigated, which may provide opportunities for novel therapeutic interventions in these debilitating diseases.
Belvisi MG, 2003, Sensory nerves and airway inflammation:: role of Aδ and C-fibres, PULMONARY PHARMACOLOGY & THERAPEUTICS, Vol: 16, Pages: 1-7, ISSN: 1094-5539
- Author Web Link
- Cite
- Citations: 53
Belvisi MG, Hele DJ, 2003, Soft steroids: a new approach to the treatment of inflammatory airways diseases, PULMONARY PHARMACOLOGY & THERAPEUTICS, Vol: 16, Pages: 321-325, ISSN: 1094-5539
- Author Web Link
- Cite
- Citations: 58
Usmani OS, Patel HJ, Belvisi MG, et al., 2002, Chocolate, chilli pepper, and cough, Winter Meeting of the British-Thoracic-Society, Publisher: BRITISH MED JOURNAL PUBL GROUP, ISSN: 0040-6376
Underwood SL, Haddad EB, Birrell MA, et al., 2002, Functional characterization and biomarker identification in the Brown Norway model of allergic airway inflammation, BRITISH JOURNAL OF PHARMACOLOGY, Vol: 137, Pages: 263-275, ISSN: 0007-1188
- Author Web Link
- Cite
- Citations: 29
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.